Venlafaxine Hydrochloride
"Venlafaxine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.
| Descriptor ID |
D000069470
|
| MeSH Number(s) |
D02.033.415.510.500.901 D02.092.471.683.948 D02.455.426.392.368.367.318.750 D10.289.510.500.901
|
| Concept/Terms |
Venlafaxine Hydrochloride- Venlafaxine Hydrochloride
- Hydrochloride, Venlafaxine
- Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
- 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl
Wy 45030- Wy 45030
- Wy-45030
- Wy45030
- Wy-45,030
- Wy 45,030
- Wy45,030
Effexor- Effexor
- Trevilor
- Vandral
- Efexor
|
Below are MeSH descriptors whose meaning is more general than "Venlafaxine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Venlafaxine Hydrochloride".
This graph shows the total number of publications written about "Venlafaxine Hydrochloride" by people in this website by year, and whether "Venlafaxine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 5 | 5 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Venlafaxine Hydrochloride" by people in Profiles.
-
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
-
Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol. 2010 Oct; 30(5):642-4.
-
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
-
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
-
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
-
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry. 2006 Nov; 67(11):1674-81.